Loading...
NPI 1174566491 · Kaneohe, HI · Community/Retail Pharmacy
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Longs Drug Stores California LLC is a community/retail pharmacy provider located in Kaneohe, Hawaii. This profile covers 9 Medicare and 8 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Longs Drug Stores California LLC |
| Address | 45 480 Kaneohe Bay Dr |
| City | Kaneohe |
| State | HI |
| ZIP | 96744 |
| Taxonomy | Community/Retail Pharmacy |
| NPI Enumerated | June 14, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $301.8K |
| Medicaid | $10.9K |
LONGS DRUG STORES CALIFORNIA LLC presents a classic community/retail pharmacy code mix focused on vaccination and point-of-care testing: its top Medicare revenue drivers are K1034 ($83K, 27.6%), 91322 ($74.6K, 24.8%) and 90694 ($42.4K, 14.1%), which together reflect immunization and COVID testing/vaccine activity. This pattern is consistent with a pharmacy that delivers routine seasonal immunizations and COVID-related services rather than high-volume clinical procedures.
Revenue concentration on Medicare is high: the precomputed top 3 Medicare codes account for 66.6% of the provider's total Medicare revenue, indicating that a relatively small set of immunization and testing services drive the majority of Medicare billing. Such concentration suggests that changes in vaccine or test demand or reimbursement for these specific codes would materially affect the provider's Medicare revenue.
On Medicaid the revenue picture is similarly concentrated but at a much smaller scale: the top Medicaid codes 0064A ($2.8K, 26.2%), 91322 ($2.1K, 19.1%) and 90471 ($2K, 18.1%) together make up 63.4% of this provider's total Medicaid revenue. This shows the provider also uses Medicaid for vaccine-related services, but Medicaid billing is a minor component of its overall payer mix.
The payer mix is heavily Medicare-weighted: lifetime Medicare revenue is $301.8K versus lifetime Medicaid revenue of $10.9K, so Medicare dominates the provider's billing footprint and the entity is effectively Medicare-centric in scale. Analysts should treat Medicaid patterns as supplemental and focused on immunization codes rather than a parallel revenue stream.
Competitively the provider reports high national percentile ranks on key Medicare codes: K1034 ranks #382 of 30143 providers (99th percentile), 91322 ranks #392 of 29357 providers (99th percentile), and 90694 ranks #523 of 51679 providers (99th percentile), indicating relatively strong national reporting volume for vaccine and COVID-test related codes. Note that the supplied descriptors label these volumes as "typical, unremarkable volume for this code," so while the provider is in high percentiles for these codes it may reflect broader industry-wide volumes for pharmacies rather than unique dominance.
In-state competitive standing on Medicaid is modest and uneven: 0064A ranks #40 of 98 providers (58th percentile) and 90471 ranks #101 of 231 providers (57th percentile), both indicating middle-of-market reporting in Hawaii, while 91322 ranks #27 of 32 providers (16th percentile), signaling relatively low Medicaid volume for that COVID vaccine code in-state. These ranks suggest the provider is not a leading Medicaid vaccine provider in Hawaii and that its Medicaid presence is limited.
Operationally the billing mix includes both product and administration codes (examples on Medicare include G0008 $24.4K, 90677 $26.5K, and 90480 $22.4K), implying the pharmacy performs vaccine administration as well as dispensing vaccine products. This combination of administration and vaccine-product codes is typical for retail pharmacies offering walk-in immunization services and seasonal vaccination campaigns.
The provider has an established NPI tenure (enumerated 2006-06-14, ~20 years ago), which indicates longstanding participation in Medicare and Medicaid; despite that tenure its cumulative billing remains modest in absolute dollars. Lifetime Medicare $301.8K and Medicaid $10.9K point to a stable but limited billing footprint, so payers and competitors should view LONGS DRUG STORES CALIFORNIA LLC as an experienced local pharmacy-level immunization/test provider rather than a high-revenue institutional source.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
9 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 7,550 | $10 | $83K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 520 | $140 | $74.6K |
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 580 | $70 | $42.4K |
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 100 | $280 | $26.5K |
| G0008 | Administration of influenza virus vaccine | 760 | $30 | $24.4K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 520 | $40 | $22.4K |
| 0134A | N/A | 330 | $40 | $14.1K |
| 90662 | This code represents a flu vaccine product that is a split virus type, contains no preservatives, and has enhanced effectiveness due to a higher antigen content. It is administered as an injection… | 170 | $70 | $12.3K |
| G0009 | Administration of pneumococcal vaccine | 90 | $10 | $800 |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 9 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
8 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 0064A | N/A | 80 | $40 | $2.8K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 20 | $120 | $2.1K |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 200 | $10 | $2K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 30 | $40 | $1.3K |
| 0012A | N/A | 20 | $40 | $880 |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 50 | $20 | $780 |
| 0134A | N/A | 10 | $40 | $520 |
| 0011A | N/A | 20 | $30 | $490 |
How this provider's Medicaid billing volume and revenue compare to other Hawaii providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Hawaii median
8 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 101 | 230 | 140 | $20 | $16.1K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 27 | 30 | 50 | $110 | $7.7K |
| 0012A | N/A | 72 | 90 | 70 | $30 | $5.6K |
| 90686 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is preservative free, uses split virus technology, and is given as a 0.5 mL… | 126 | 180 | 120 | $10 | $4.7K |
| 0011A | N/A | 78 | 90 | 80 | $20 | $4.4K |
| 0064A | N/A | 40 | 100 | 60 | $30 | $3.2K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 38 | 60 | 50 | $30 | $2.8K |
| 0134A | N/A | 33 | 40 | 30 | $30 | $1.5K |
Other providers in the same ZIP code as Longs Drug Stores California LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.